Arcus Biosciences (RCUS)

Company Profile

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.

Company profile

Ticker

RCUS

Exchange

NYSE

Website

www.arcusbio.com

CEO

Terry J. Rosen

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001724521

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Arcus Biosciences Australia PTY LTD ...

RCUS stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$36.67

Low target

$33.00

High target

$42.00

Latest filings (excl ownership)

View all

2 Nov 22

Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update

2 Nov 22

S-3ASR

Automatic shelf registration

11 Oct 22

8-K

Entry into a Material Definitive Agreement

3 Aug 22

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

3 Aug 22

8-K

Submission of Matters to a Vote of Security Holders

Transcripts

Earnings call transcript

2021 Q2

7 Aug 21

Latest ownership filings

View all

Change in insider ownership

Financial summary

Financial statements Chart RCUS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	220.65 mm	220.65 mm	220.65 mm	220.65 mm	220.65 mm	220.65 mm
Cash burn (monthly)	18.33 mm	(no burn)	23.13 mm	(no burn)	26.99 mm	(no burn)
Cash used (since last report)	77.40 mm	n/a	97.70 mm	n/a	113.97 mm	n/a
Cash remaining	143.25 mm	n/a	122.95 mm	n/a	106.68 mm	n/a
Runway (months of cash)	7.8	n/a	5.3	n/a	4.0	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

RCUS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	181	176	+2.8%
Opened positions	25	52	-51.9%
Closed positions	20	36	-44.4%
Increased positions	79	64	+23.4%
Reduced positions	52	32	+62.5%

13F shares	Current	Prev Q	Change
Total value	1.27 bn	1.34 bn	-5.0%
Total shares	78.08 mm	82.26 mm	-5.1%
Total puts	167.10 k	903.30 k	-81.5%
Total calls	156.50 k	380.60 k	-58.9%
Total put/call ratio	1.1	2.4	-55.0%

Largest owners	Shares	Value	Change
GILD Gilead Sciences	22.72 mm	$0.00	0.0%
BLK Blackrock	8.93 mm	$233.56 mm	+9.9%
Vanguard	4.46 mm	$116.60 mm	+4.1%
Biotechnology Value Fund L P	3.96 mm	$0.00	0.0%
Partner Fund Management	3.38 mm	$88.51 mm	+1.1%
FMR	3.36 mm	$87.77 mm	+1.0%
BVF	2.72 mm	$71.08 mm	-31.4%
Octagon Capital Advisors	2.67 mm	$69.80 mm	-0.1%
GV 2016	2.56 mm	$0.00	0.0%
Invus Financial Advisors	1.61 mm	$42.17 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-4.44 mm	EXIT
BVF	2.72 mm	-1.24 mm	-31.4%
BLK Blackrock	8.93 mm	+805.53 k	+9.9%
Perceptive Advisors	666.48 k	+666.48 k	NEW
Pictet Asset Management	1.49 mm	-423.11 k	-22.1%
Balyasny Asset Management	0.00	-408.12 k	EXIT
Sofinnova Investments	381.35 k	+381.35 k	NEW
Dimensional Fund Advisors	680.09 k	+359.34 k	+112.0%
Orbimed Advisors	303.00 k	+303.00 k	NEW
MS Morgan Stanley	353.06 k	-230.64 k	-39.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RCUS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 23	Jarrett Jennifer	Common Stock	Sell	Dispose S	No	Yes	23.52	1,600	37.63 k	414,946
26 Jan 23	Jarrett Jennifer	Common Stock	Sell	Dispose S	No	Yes	23.56	300	7.07 k	416,546
23 Jan 23	Rosen Terry J	Common Stock	Grant	Acquire A	No	No	0	105,700	0.00	469,123
23 Jan 23	Rosen Terry J	Stock Option Common Stock	Grant	Acquire A	No	No	22.02	429,000	9.45 mm	429,000
23 Jan 23	Jaen Juan C.	Common Stock	Grant	Acquire A	No	No	0	45,800	0.00	324,682
23 Jan 23	Jaen Juan C.	Stock Option Common Stock	Grant	Acquire A	No	No	22.02	185,900	4.09 mm	185,900
23 Jan 23	Jarrett Jennifer	Common Stock	Grant	Acquire A	No	No	0	45,800	0.00	416,846
23 Jan 23	Jarrett Jennifer	Stock Option Common Stock	Grant	Acquire A	No	No	22.02	185,900	4.09 mm	185,900
23 Jan 23	Carolyn C. Tang	Common Stock	Grant	Acquire A	No	No	0	34,000	0.00	97,539
23 Jan 23	Carolyn C. Tang	Stock Option Common Stock	Grant	Acquire A	No	No	22.02	138,200	3.04 mm	138,200